Rafael Holdings, Inc. (RFL) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended October 31, 2025. Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical-stage companies. The primary strategic focus is the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). On March 25, 2025, the Company consummated a merger with Cyclo Therapeutics, LLC, making it a wholly-owned subsidiary. The Company operates through three segments: Healthcare, Infusion Technology, and Real Estate.
Key Financial Metrics
| Metric | Q1 2026 (Oct 31, 2025) | Q1 2025 (Oct 31, 2024) |
|---|---|---|
| Total Revenue | $240,000 | $128,000 |
| Net Loss (Consolidated) | $(9,797,000) | $(9,211,000) |
| Net Loss Attributable to RFL | $(9,816,000) | $(9,006,000) |
| Loss Per Share (Basic & Diluted) | $(0.19) | $(0.37) |
| Cash and Cash Equivalents | $45,539,000 | $8,159,000 |
| Working Capital | $36,245,000 | $45,114,000 |
| Total Assets | $105,375,000 | $114,109,000 |
| Total Liabilities | $16,195,000 | $15,738,000 |
Segment Performance:
- Healthcare: Revenue of $154,000 (primarily product revenue from Cyclo); Operating Loss of $(10,124,000). R&D expenses surged to $7.48 million due to Cyclo consolidation.
- Infusion Technology: Revenue of $0 (down from $51,000) following the sale of assets and licensing of Unlokt™ technology in March 2025.
- Real Estate: Revenue of $86,000; Operating Income of $12,000.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 88% to $240,000, driven by the inclusion of Cyclo's product revenue ($154,000) following the March 2025 merger. Conversely, Infusion Technology revenue dropped to zero after the sale of Day Three Labs Manufacturing assets.
- Operating Expenses: Operating loss widened to $(10.14 million) from $(3.84 million). This was primarily due to a $6.3 million increase in R&D expenses and a $0.46 million increase in G&A expenses, both largely attributable to the consolidation of Cyclo's operations.
- Non-Operating Items: The prior period included significant unrealized losses on the investment in Cyclo ($(4.37 million)) and convertible notes ($(1.59 million)). These items are absent in the current period as the investment was converted into a wholly-owned subsidiary.
- Liquidity: Cash balances increased significantly to $45.5 million from $8.2 million in the prior year, bolstered by a rights offering and private placement in June 2025 where related parties purchased approximately $21 million of unsubscribed shares.
Outlook, Risks, and Contingencies
- Liquidity Outlook: Management expects cash and cash equivalents of $45.5 million to be sufficient to meet obligations for at least the next 12 months.
- Strategic Focus: The Company is evaluating its portfolio to ensure resources are focused on core assets, specifically the Trappsol® Cyclo™ Phase 3 clinical trial.
- Internal Controls: Management identified a material weakness in internal control over financial reporting at the acquired Cyclo subsidiary regarding the accrual and recognition of expenses (specifically clinical trial accruals). A remediation plan is underway to integrate Cyclo's processes into the Company's existing controls.
- Debt Obligations: Cornerstone Pharmaceuticals holds Series C Convertible Notes totaling approximately $659,000 in principal. A portion ($608,000) is currently in default as it is beyond the maturity date, though settlement agreements were reached for a small portion during the quarter.
- Related Party Transactions: Significant transactions include a $21 million private placement by related parties of the Chairman and ongoing rental income from IDT Corporation (a related party).
Investor Verification Checklist
- Cyclo Integration: Verify the progress of the Phase 3 clinical trial for Trappsol® Cyclo™ and the timeline for regulatory approval.
- Internal Control Remediation: Monitor the status of the remediation plan for the material weakness identified at Cyclo regarding expense accruals.
- Cornerstone Debt: Review the status of the defaulted Series C Convertible Notes at Cornerstone and any potential restructuring or settlement impacts.
- Capital Sufficiency: Confirm that the $45.5 million cash balance remains adequate given the high burn rate associated with clinical trials (R&D expenses of $7.5M in one quarter).
- Related Party Influence: Note that the Chairman (Howard S. Jonas) controls approximately 51% of the combined voting power and was a key backstop for the recent capital raise.